CSI Market
Sign In | Register

Phio Pharmaceuticals (PHIO) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PHIO Annual Cash Flow →
Examining cash flow movements between Phio Pharmaceuticals and Jun 30 2025 reveals how Jun 30 2026 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-8.14
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.60
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Net Income Loss Including Other-
Non Cash Rent Expense-
Fair Value Of Derivatives Issued In Exchange For Services-
Fair Value Of Common Stock Issued In Exchange For Services Or Claims-
Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financing-
Fair Value Of Common Stock Issued In Exchange For Licensing Rights-
Stock Issued-
Fair Value Of Derivatives Issued In Connection With Parent Company Common Stock Recorded As Cost Of Equity-
Fair Value Of Parent Company Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants-
Allocation Of Management Expenses-
Noncash Rent Expense-
Conversion Of Stock Amount Converted-
Preferred Stock Beneficial Conversion Feature-
Temporary Equity Accretion To Redemption Value-
Research And Development Intangibles Purchased From Others-
Predecessor Research And Development Intangibles Purchased From Others-
Gain Loss On Derivative Instruments Net Pretax-
Fair Value Of Shares Mandatorily Redeemable For Cash Upon Exercise Of Warrants-
Increase Decrease In Operating Lease Liability-
Increase Decrease In Operating Lease Liabilities-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.47
Increase (Decrease) in Accrued Liabilities-0.10
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.86
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.72
Discontinued operations0.00
Net Cash flow from Operating Activities-8.04
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Refunded Paid For Lease Deposit-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Cash Contributions From Parent Company Net-
Net Proceeds From Issuance Of Convertible Notes Payable-
Cash Paid In Lieu Of Fractional Shares-
Cash Paid In Lieu Of Fractional Shares For Reverse Stock Split-
Forgiveness Of Debt-
Cash In Lieu Of Fractional Shares For Reverse Stock Split-
Proceeds From Issuance Of Common Stock And Warrants8.35
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-8.04
Total Cash Flow-8.04
4 historic quarters locked

Sign in to unlock the full Phio Pharmaceuticals cash flow history.

Sign In Create Free Account

About Phio Pharmaceuticals Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-026271

Figures are derived from filed reports and may be restated. Historical data is subject to revision.